A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan

International Clinical Psychopharmacology

Volumn 20, Issue 5, 2005, Pages 265-273

  Kamijima, Kunitoshi ^a   Kuboki, Tomifusa ^b   Kumano, Hiroaki ^b   Burt, Tal ^c,d   Cohen, Guy ^c   Arano, Ichiro ^c   Hamasaki, Toshimitsu ^e  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c PFIZER INC   (United States)

^d Columbia University College of Physicians and Surgeons ^*  (United States)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Japan; Panic disorder; Sertraline

Indexed keywords

PLACEBO; SERTRALINE;

ADULT; AGORAPHOBIA; ARTICLE; ASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; JAPAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NAUSEA; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; RHINOPHARYNGITIS; SOMNOLENCE; TREATMENT WITHDRAWAL; XEROSTOMIA;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SEVERITY OF ILLNESS INDEX;

EID: 23944460548     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000171518.25963.63     Document Type: Article

References (33)

1. American Psychiatric Association (1998). Practice guideline for the treatment of panic disorder. Am J Psychiatry 155 (suppl):1-34.
2. Aoki Y, Fujihara S, Kitamura T (1994). Panic attacks and panic disorder in a Japanese non-patient population: epidemiology and psychosocial correlates. J Affect Disord 32:51-59.
3. Baldwin DS, Birtwistle J (1998). The side effect burden associated with drug treatment of panic disorder. J Clin Psychiatry 59 (suppl 8):39-44.
4. Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Baldwin DS, den Boer JA, et al. (1998). Consensus statement on panic disorder from the International Consensus Group on depression and anxiety. J Clin Psychiatry 59 (suppl 8):47-54.
5. Bandelow B, Behnke K, Lenoir S, Hendriks GJ, Alkin T, Goebel C, et al. (2004). Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind, non-inferiority comparison. J Clin Psychiatry 65: 405-413.
6. Basoglu M, Marks IM, Kilic C, Swinson RP, Noshirvani H, Kuch K, et al. (1994). Relationship of panic, anticipatory anxiety, agoraphobia, and global improvement in panic disorder with agoraphobia treated with alprazolam and exposure. Br J Psychiatry 164:647-652.
7. Boyer W (1995). Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 10:45-49.
8. Candilis PJ, McLean RY, Otto MW, Manfro GG, Worthington JJ III, Penava SJ, et al. (1999). Quality of life in patients with panic disorder. J Nerv Ment Dis 187:429-434.
9. Davidson JR (1998). The long-term treatment of panic disorder. J Clin Psychiatry 59 (suppl 8):17-21.
10. Fyer AJ, Katon W, Hollifield M, Rassnick H, Mannuzza S, Chapman T, et al. (1996). The DSM-IV panic disorder field trial: panic attack frequency and functional disability. Anxiety 2:157-166.
11. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC: US Dept of Health, Education and Welfare, pp. 217-222.
12. Hamilton M (1967). Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
13. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
14. Hollifield M, Katon W, Skipper B, Chapman T, Ballenger JC, Mannuzza S, et al. (1997). Panic disorder and quality of life: variables predictive of functional impairment. Am J Psychiatry 154:766-772.
15. Judge R, Steiner M (1996). The long-term efficacy and safety of paroxetine in panic disorder (abstract). Eur Neuropsychopharmacol 6 (suppl 3):207.
16. Lecrubier Y, Judge R (1997). Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 95:153-160.
17. Lepola U, Arato M, Zhu Y, Austin C (2003). Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry 64:654-662.
18. Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjodin I, et al. (1998). A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 59:528-534.
19. Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, et al. (1998). Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 173:54-60.
20. Mavissakalian MR, Perel JM (2002). Duration of imipramine therapy and relapse in panic disorder with agoraphobia. J Clin Psychopharmacol 22:294-299.
21. Michelson D, Pollack M, Lydiard RB, Tamura R, Tepner R, Tollefson G (1999). Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. Br J Psychiatry 174:213-218.
22. Pohl RB, Wolkow RM, Clary CM (1998). Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 155:1189-1195.
23. Pollack MH, Smoller JW (1995). The longitudinal course and outcome of panic disorder. Psychiatr Clin North Am 18:785-801.
24. Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R (1998). Sertraline in the treatment of panic disorder: a flexible dose multicenter trial. Arch Gen Psychiatry 55:1010-1016.
25. Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH, Hollander E, et al. (2003). World Council of Anxiety. WCA recommendations for the long-term treatment of panic disorder. CNS Spectr 8 (suppl 1):17-30.
26. Roy-Byrne PP, Clary CM, Miceli RJ, Colucci SV, Xu Y, Grudzinski AN (2001). The effect of selective serotonin reuptake inhibitor treatment of panic disorder on emergency room and laboratory resource utilization. J Clin Psychiatry 62:678-682.
27. Rubin HC, Rapaport MH, Levine B, Gladsjo JK, Rabin A, Auerbach M, et al. (2000). Quality of well being in panic disorder: the assessment of psychiatric and general disability. J Affect Disord 57:217-221.
28. Satoh K, Fuji I (1992). Current views on panic disorder and its management in Japan: a national survey. Jpn J Psychiatry Neurol 46:45-53.
29. Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, et al. (1997). Multi-center collaborative Panic Disorder Severity Scale. Am J Psychiatry 154:1571-1575.
30. Shear MK, Clark D, Feske U (1998). The road to recovery in panic disorder: response, remission, and relapse. J Clin Psychiatry 59 (suppl 8):4-8.
31. Sheikh JI, Londborg P, Clary CM, Fayyad R (2000). The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies. Int Clin Psychopharmacology 15:335-342.
32. Tajima O (2001). Mental health care in Japan: recognition and treatment of depression and anxiety disorders. J Clin Psychiatry 62 (suppl 13):39-44.
33. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, et al. (1997). The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 54:305-309.